Online comparisons often jump to "which melts more fat." A more useful frame is: what is FDA-approved for what, what large trials actually measured, what side effects and contraindications look like, and how your medical history changes the choice. Brand products (for example, Wegovy® for semaglutide 2.4 mg chronic weight management; Zepbound® for tirzepatide weight management) have labeled indications, dosing schedules, and boxed warnings. Compounded products are a different regulatory category.
What it is
Semaglutide is a GLP-1 receptor agonist. At weight-management doses, FDA-approved injectable semaglutide (Wegovy) is indicated, with reduced-calorie diet and increased physical activity, for chronic weight management in eligible adults (and certain adolescents) and has additional labeled uses such as cardiovascular risk reduction in defined populations—see the current prescribing information.
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. FDA-approved tirzepatide for weight management (Zepbound) is indicated with diet and activity for chronic weight management in eligible adults; labeling also includes other uses (e.g., obstructive sleep apnea in adults with obesity in updated labeling). Always check the current AccessData label for the product you discuss with a clinician.
Neither article summary replaces the label. Diabetes-branded versions (Ozempic®, Mounjaro®) have overlapping active ingredients but different approved indications and dosing—using a diabetes pen "off-label for weight" is a clinician decision, not a blog protocol.
How it works
Both medicines reduce appetite and calorie intake and slow gastric emptying to varying degrees over time. Tirzepatide's dual agonism is designed to engage GIP and GLP-1 pathways; labels note greater fat-mass than lean-mass loss with weight reduction, which is not the same as "zero muscle loss."
Clinical use typically involves gradual dose escalation to improve gastrointestinal tolerability. Stopping therapy often leads to weight regain in obesity trials—chronic disease framing matters.
What evidence shows
| Comparison point | Evidence type | Takeaway |
|---|---|---|
| Semaglutide 2.4 mg vs placebo for weight (STEP 1) | Established RCT | ~14.9% mean weight loss at 68 weeks vs ~2.4% placebo (Wilding et al., NEJM 2021) |
| Tirzepatide 5/10/15 mg vs placebo (SURMOUNT-1) | Established RCT | ~15–21% mean weight loss at 72 weeks depending on dose vs ~3% placebo (Jastreboff et al., NEJM 2022) |
| Tirzepatide vs semaglutide head-to-head in obesity without diabetes (SURMOUNT-5) | Established RCT | Tirzepatide superior for weight and waist reduction at 72 weeks in that trial (~20.2% vs ~13.7%) (NEJM 2025) |
| Cross-trial "X% beats Y%" from STEP vs SURMOUNT alone | Indirect / weaker | Different populations and designs; prefer head-to-head when available |
| Semaglutide CV outcomes in obesity + CVD without diabetes (SELECT) | Established RCT | Reduced major adverse CV events vs placebo (Lincoff et al., NEJM 2023) |
| Compounded semaglutide/tirzepatide equals brand outcomes | Unproven | Compounded products are not FDA-approved; quality, dosing accuracy, and evidence base differ |
Proven vs unproven (plain language): Large RCTs prove meaningful average weight loss versus placebo for labeled products used as studied. They do not prove that every man will match the mean, that lean mass is fully preserved without lifestyle support, or that compounded copies match brand pharmacokinetics.
Risks
Shared class themes (see current labels):
- Boxed warning: risk of thyroid C-cell tumors in rodents; contraindicated with personal/family history of medullary thyroid carcinoma (MTC) or MEN2
- Gastrointestinal effects (nausea, vomiting, diarrhea, constipation)—often dose-related during escalation
- Gallbladder disease, pancreatitis warnings, dehydration/AKI risk with severe GI losses
- Delayed gastric emptying considerations (including perioperative aspiration risk language on some labels)
- Hypoglycemia risk when combined with insulin or sulfonylureas
- Rapid weight loss can include lean mass decline on DXA—not identical to skeletal muscle, but clinically relevant for strength planning
Individual eligibility (BMI thresholds, comorbidities), insurance/cash-pay access, and monitoring plans belong in a clinical visit.
Who should discuss with a clinician
Discuss options if you have obesity or overweight with weight-related conditions and want evidence-based pharmacotherapy plus lifestyle support. Be especially careful to review history of MTC/MEN2, pancreatitis, severe GI disease, pregnancy plans, gallbladder disease, and all current medicines. Men also using testosterone therapy need coordinated monitoring (see our related education on stacking)—combination is not automatically indicated.
Bottom Line
Tirzepatide showed greater average weight loss than semaglutide in a direct obesity trial (SURMOUNT-5), while both are strongly effective versus placebo in their pivotal programs. "Right for you" still depends on labeled indication, contraindications, tolerability, comorbidities (including CV disease), cost/access, and clinician judgment—not a ranking tweet.
So what?
Bring your full medication list, weight history, and goals (metabolic health vs scale only) to a licensed provider. Ask specifically whether they mean an FDA-approved product or a compounded preparation, and what monitoring they recommend.
For an overview of how Scoreboard Health frames men's metabolic care with licensed clinicians, see Treatments or How it works.
Related reading
Disclaimer: Educational only—not medical advice. Brand names are trademarks of their owners. Compounded medications are not FDA-approved. Read current FDA labels before any therapy discussion.
Medically reviewed by: Ariel Bowerman, BSN, R.N.
Sources
- Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). N Engl J Med. 2021. nejm.org
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022. nejm.org
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025. nejm.org
- Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023. nejm.org
- FDA AccessData — WEGOVY (semaglutide) prescribing information. accessdata.fda.gov
- FDA AccessData — ZEPBOUND (tirzepatide) prescribing information. accessdata.fda.gov
Learn how Scoreboard Health structures men's evaluation pathways: How it works · Treatments